Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for IMMURON (IMRN : NSDQ)

• Company Description    Immuron Limited is a bio pharmaceutical Microbiome company. It focused on oral immunotherapy using polyclonal antibody products for humans. The company is involved in developing therapeutic products in NASH, ASH and other diseases mediated through gut disbiosis. Immuron Limited is based in Armadale, Australia. Number of Employees: 7

• Price / Volume Information    Yesterday's Closing Price: $1.91 Daily Weekly Monthly 20 Day Moving Average: 16,041 shares Shares Outstanding: 5.84 (millions) Market Capitalization: $11.16 (millions) Beta: 0.95 52 Week High: $2.87 52 Week Low: $1.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 15.76% 7.74% 12 Week -5.44% 2.17% Year To Date 12.35% 19.11%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 62 LYGON STREET LEVEL 3 - CARLTON,C3 3053 AUS ph: 610398245254 fax: 6103 98227735 dave@redchip.com http://www.immuron.com.au

• General Corporate Information    Officers Steven Lydeamore - Chief Executive Officer Paul Brennan - Chairman Jerry Kanellos - Chief Operating Officer Phillip Hains - Chief Financial Officer Flavio Palumbo - Chief Commercial Officer Peer Information IMMURON (CORR.) IMMURON (RSPI) IMMURON (CGXP) IMMURON (BGEN) IMMURON (GTBP) IMMURON (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45254U101 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 5.84 Most Recent Split Date: (:1) Beta: 0.95 Market Capitalization: $11.16 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.66 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/25 - - 12/31/24 - - 09/30/24 - - ROA 03/31/25 - - 12/31/24 - - 09/30/24 - - Current Ratio 03/31/25 - - 12/31/24 - 6.80 09/30/24 - - Quick Ratio 03/31/25 - - 12/31/24 - 5.92 09/30/24 - - Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Pre-Tax Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Book Value 03/31/25 - - 12/31/24 - 1.15 09/30/24 - - Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Capital 03/31/25 - - 12/31/24 - - 09/30/24 - -

Powered by Zacks Investment Research ©